• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Power3 Medical Products and the Princess Haya Biotechnology Center, Jordan University of Science and Technology, Collaborate in a Clinical Validation Study of the BC-SeraPro(TM) Breast Cancer Diagnostic Blood Test

Posted on: Tuesday, 15 July 2008, 12:00 CDT

Power3 Medical Products, Inc. (OTCBB:PWRM), a leading proteomics company specializing in the development and commercialization of early detection diagnostic tests for breast cancer and neurodegenerative diseases, today announced a new major international collaboration. Power3, in partnership with the Princess Haya Biotechnology Center and the Jordan University of Science and Technology will begin a clinical validation study for Power3's BC-SeraPro(TM) Breast Cancer diagnostic blood test. The collaborative project will significantly expand Power3's already-extensive breast cancer patient database and will further validate the pioneering work Power3 has already completed in the discovery of blood serum-based biomarkers of disease.

The Princess Haya Biotechnology Center and the Jordan University of Science and Technology will provide Power3 with clinically confirmed breast cancer, benign breast disease and age-matched control patient samples. Power3 will use its proprietary and patent-pending technologies to analyze these samples, in a further validation of the company's panel of protein biomarkers for the early detection of breast cancer.

Power3 has previously reported results of a 60 patient, blinded breast cancer detection validation study. Using one of the company's proprietary bio-analytical methods, this validation study produced results of 97% sensitivity and 93% specificity. In addition, using a more robust and flexible bio-analytical statistical model, Power3 achieved 80% sensitivity and 87% specificity in the blinded breast cancer detection study.

Once commercialized, BC-SeraPro(TM) will have an enormous impact on how breast cancer will be diagnosed, monitored, and managed. Steven B. Rash, chairman and CEO of Power3, said he is hopeful that this collaboration with the Princess Haya Biotechnology Center will prove a major milestone towards offering the medical community a test that is accurate, utilitarian and inexpensive in the Middle East and in other international markets. The company expects to complete the clinical validation study in the third quarter 2008, and introduce the BC-SeraPro(TM) commercially in the first quarter of 2009.

"We will work hard with Power3 Medical Products to move the BC-SeraPro(TM) Breast Cancer Diagnostic Blood Test rapidly through the validation phase using serum from Middle Eastern women with breast cancer. In Jordan, breast cancer is the leading form of cancer among women and the second leading cause of death in women. Building on the existing Proteome Systems Discovery effort by Power3 Medical Products', we believe that this collaboration, which combines The Princess Haya Biotechnology Center's developmental capabilities in DNA sequencing, gene-expression and proteomic profiling, and Power3 Medical Products', cutting edge proteomics platform, will lead to the development of a new breast cancer diagnostic utilizing protein biomarkers which can be applicable regardless of a woman's genetic makeup or ethnicity. We look forward to working with Power3 to extend this powerful combination of technologies and expertise to other life-threatening diseases relevant to the region," said Dr. Saied Jaradat, Principal Investigator and Director of the Princess Haya Biotechnology Center.

In addition to the BC-Sera Pro(TM) test, Power3 is currently evaluating its NuroPro(R) early detection blood serum test for Parkinson's disease in clinical validation studies in collaboration with the University of Thessaly Medical School in Greece and the Cleo Roberts Center for Clinical Research at the Sun Health Research Institute in Sun City, Arizona. The Company's NuroPro(R) blood serum diagnostic test for the early detection of Parkinson's and Alzheimer's diseases is in the final stages of clinical validation and is expected to be introduced into international markets later this year, followed closely by introduction in the United States.

About Power3 Medical Products

Power3 Medical Products, Inc. (OTCBB:PWRM, www.Power3Medical.com), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 has signed its first distribution agreement to provide its blood serum diagnostic for breast cancer, BC-SeraPro(TM), in twelve Middle Eastern countries before the end of 2008. Power3 operates a state-of-the-art CLIA certified proteomics laboratory in The Woodlands (Houston), Texas. The Company is preparing to commercialize its IP portfolio, centering on the 543 biomarkers the Company has discovered from a broad range of diseases as the basis of blood-based tests for breast cancer, ALS, Alzheimer's, and Parkinson's Diseases.

About The Princess Haya Biotechnology Center

The Princess Haya Biotechnology Center was established at the Jordan University of Science and Technology on the campus of King Abdullah University Hospital, March 10, 2005. The center has provided faculty members and graduate students from different disciplines at the university with an excellent, unprecedented infrastructure for experimental research in biotechnology, especially in the fields of genomics and proteomics. Since its establishment, The Princess Haya Biotechnology Center has been a pillar of the scientific activity in Jordan through the cooperation agreements with the local institutions and hospitals dealing with genetic diseases in Jordan and through the continuous scientific activities at the national and regional levels.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.

Source: Business Wire

More News in this Category